Origines

Origines is a French biotechnology company dedicated to the discovery and development of first-in-class small molecule drugs for the treatment of chronic inflammatory and autoimmune diseases. Founded in 2020 and headquartered in Paris, the company focuses on the "inflammaging" concept, specifically targeting the modulation of Toll-like receptors (TLRs) such as TLR7, TLR8, and TLR9. Their research leverages deep expertise in plasmacytoid dendritic cell (pDC) biology and Type I interferon production to address the root causes of immune dysregulation. Origines' lead programs are currently in the pre-clinical stage, with a primary focus on indications like systemic lupus erythematosus and psoriasis. The company is a spin-off from the CNRS and the University of Paris and is supported by leading venture capital firms like Kurma Partners.